67 related articles for article (PubMed ID: 20868603)
1. [Expressions of Raf-1 kinase, phosphorylated mitogen extracellular kinase 1, and phosphorylated extracellular signal-regulated protein kinase 1/2 in hepatocellular carcinoma and their relationship with prognosis].
Chen L; Shi Y; Jiang CY; Sun Q; Dai GH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):424-8. PubMed ID: 20868603
[TBL] [Abstract][Full Text] [Related]
2. Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma.
Chen L; Shi Y; Jiang CY; Wei LX; Wang YL; Dai GH
Eur J Surg Oncol; 2011 Jun; 37(6):513-20. PubMed ID: 21324414
[TBL] [Abstract][Full Text] [Related]
3. Mitogen-activated protein kinase pathway in osteosarcoma.
Na KY; Kim YW; Park YK
Pathology; 2012 Oct; 44(6):540-6. PubMed ID: 22935974
[TBL] [Abstract][Full Text] [Related]
4. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
Wong H; Belvin M; Herter S; Hoeflich KP; Murray LJ; Wong L; Choo EF
J Pharmacol Exp Ther; 2009 Apr; 329(1):360-7. PubMed ID: 19147858
[TBL] [Abstract][Full Text] [Related]
6. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
7. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection.
Schmitz KJ; Wohlschlaeger J; Lang H; Sotiropoulos GC; Malago M; Steveling K; Reis H; Cicinnati VR; Schmid KW; Baba HA
J Hepatol; 2008 Jan; 48(1):83-90. PubMed ID: 17998146
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
Wen-Sheng W
Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
[TBL] [Abstract][Full Text] [Related]
9. Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma.
McKillop IH; Schmidt CM; Cahill PA; Sitzmann JV
Hepatology; 1997 Dec; 26(6):1484-91. PubMed ID: 9397988
[TBL] [Abstract][Full Text] [Related]
10. [Expression of Raf kinase inhibitor protein and its significance in invasion and metastasis of hepatocellular carcinoma].
Wu XH; Wang SX; Yang YJ; Li JK; Xu Z; Tang RF
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):358-62. PubMed ID: 21875465
[TBL] [Abstract][Full Text] [Related]
11. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
[TBL] [Abstract][Full Text] [Related]
12. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma.
Ito Y; Sasaki Y; Horimoto M; Wada S; Tanaka Y; Kasahara A; Ueki T; Hirano T; Yamamoto H; Fujimoto J; Okamoto E; Hayashi N; Hori M
Hepatology; 1998 Apr; 27(4):951-8. PubMed ID: 9537433
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
14. Involvement of protein kinase C beta-extracellular signal-regulating kinase 1/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion.
Guo K; Liu Y; Zhou H; Dai Z; Zhang J; Sun R; Chen J; Sun Q; Lu W; Kang X; Chen P
Cancer Sci; 2008 Mar; 99(3):486-96. PubMed ID: 18167130
[TBL] [Abstract][Full Text] [Related]
15. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
16. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
[TBL] [Abstract][Full Text] [Related]
17. Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases.
Pan MR; Chang HC; Hung WC
Cell Signal; 2008 Jun; 20(6):1134-41. PubMed ID: 18374541
[TBL] [Abstract][Full Text] [Related]
18. Distribution, levels and phosphorylation of Raf-1 in Alzheimer's disease.
Mei M; Su B; Harrison K; Chao M; Siedlak SL; Previll LA; Jackson L; Cai DX; Zhu X
J Neurochem; 2006 Dec; 99(5):1377-88. PubMed ID: 17064357
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
20. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors.
Yoshida T; Hisamoto T; Akiba J; Koga H; Nakamura K; Tokunaga Y; Hanada S; Kumemura H; Maeyama M; Harada M; Ogata H; Yano H; Kojiro M; Ueno T; Yoshimura A; Sata M
Oncogene; 2006 Oct; 25(45):6056-66. PubMed ID: 16652141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
